Literature DB >> 22723757

When should combination therapy for patients with Crohn's disease be discontinued?

Jean-Frédéric Colombel1.   

Abstract

Entities:  

Year:  2012        PMID： 22723757      PMCID： PMC3380260     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  5 in total

1.  Understanding combination therapy with biologics and immunosuppressives for the treatment of Crohn's disease.

Authors:  Jean-Frederic Colombel
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-08

Review 2.  The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

Authors:  Geert R D'Haens; Remo Panaccione; Peter D R Higgins; Severine Vermeire; Miquel Gassull; Yehuda Chowers; Stephen B Hanauer; Hans Herfarth; Daan W Hommes; Michael Kamm; Robert Löfberg; A Quary; Bruce Sands; A Sood; G Watermeyer; G Watermayer; Bret Lashner; Marc Lémann; Scott Plevy; Walter Reinisch; Stefan Schreiber; Corey Siegel; Stephen Targan; M Watanabe; Brian Feagan; William J Sandborn; Jean Frédéric Colombel; Simon Travis
Journal:  Am J Gastroenterol       Date:  2010-11-02       Impact factor: 10.864

3.  Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.

Authors:  Edouard Louis; Jean-Yves Mary; Gwenola Vernier-Massouille; Jean-Charles Grimaud; Yoram Bouhnik; David Laharie; Jean-Louis Dupas; Hélène Pillant; Laurence Picon; Michel Veyrac; Mathurin Flamant; Guillaume Savoye; Raymond Jian; Martine Devos; Raphaël Porcher; Gilles Paintaud; Eric Piver; Jean-Frédéric Colombel; Marc Lemann
Journal:  Gastroenterology       Date:  2011-09-22       Impact factor: 22.682

Review 4.  Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change.

Authors:  Ingrid Ordás; Brian G Feagan; William J Sandborn
Journal:  Gut       Date:  2011-10-13       Impact factor: 23.059

5.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.

Authors:  Gert Van Assche; Charlotte Magdelaine-Beuzelin; Geert D'Haens; Filip Baert; Maja Noman; Séverine Vermeire; David Ternant; Hervé Watier; Gilles Paintaud; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682
  5 in total
  2 in total

1.  Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting.

Authors:  Joshua C Berkowitz; Joanna Stein-Fishbein; Sundas Khan; Richard Furie; Keith S Sultan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2018-02-06

2.  Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases.

Authors:  Gerard Honig; Paul B Larkin; Caren Heller; Andrés Hurtado-Lorenzo
Journal:  Inflamm Bowel Dis       Date:  2021-11-15       Impact factor: 5.325
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.